Event JSON
{
"id": "e074c62707c71f7908ca557f60b93f4bc5c67464b18b19f78c56ec5470dd97e0",
"pubkey": "9c41d1165a76eda7abb3db9d665e67fdd23320dd1a8c6a65ff40a65935d667cc",
"created_at": 1738671380,
"kind": 1,
"tags": [
[
"r",
"https://www.cnbc.com/2025/02/04/pfizer-pfe-earnings-q4-2024.html"
],
[
"subject",
"Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off"
],
[
"published_at",
"1738671145"
],
[
"image",
"https://image.cnbcfm.com/api/v1/image/108095049-17382606532024-05-22t162957z_958875141_rc2sv7ar6muk_rtrmadp_0_wsj-future-of-everything.jpeg?v=1738260784\u0026w=1920\u0026h=1080"
],
[
"p",
"9c41d1165a76eda7abb3db9d665e67fdd23320dd1a8c6a65ff40a65935d667cc",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://image.cnbcfm.com/api/v1/image/108095049-17382606532024-05-22t162957z_958875141_rc2sv7ar6muk_rtrmadp_0_wsj-future-of-everything.jpeg?v=1738260784\u0026w=1920\u0026h=1080"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"Pfizer's fourth-quarter earnings and revenue exceeded expectations, with the company reporting adjusted earnings per share of 63 cents and revenue of $17.76 billion. The company's Covid products and cancer drugs from its acquisition of Seagen contributed to the strong results. Pfizer reiterated its full-year 2025 outlook, forecasting sales of $61 billion to $64 billion, but noted that changes to the Medicare program will hurt sales by $1 billion. The company's long-term financial health and drug pipeline are also being closely watched, particularly the commercial success of its acquisition of Seagen and the potential of its experimental obesity pill, danuglipron."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqn3qaz9j6wmk602anmwwkvhn8lhfrxgxar2xx5e0lgzn9jdwkvlxqy56fv4\nhttps://image.cnbcfm.com/api/v1/image/108095049-17382606532024-05-22t162957z_958875141_rc2sv7ar6muk_rtrmadp_0_wsj-future-of-everything.jpeg?v=1738260784\u0026w=1920\u0026h=1080\nThe results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.\nhttps://www.cnbc.com/2025/02/04/pfizer-pfe-earnings-q4-2024.html",
"sig": "50520548080369013489c226f35c1c26b9156efbead9d2c53ab694fc7e13764da89f2d7fd079dab654a2d5edf5a8c1700efe536434b6ca5f1420187db5814f24"
}
